Dario Cattaneo

Summary

Affiliation: University of Milan
Country: Italy

Publications

  1. ncbi Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing
    Dario Cattaneo
    Department of Infectious Diseases, L Sacco University Hospital, Milan, Italy
    Antimicrob Agents Chemother 56:6132-6. 2012
  2. ncbi Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects
    Dario Cattaneo
    Unit of Clinical Pharmacology, Luigi Sacco University Hospital, Universita di Milano, Milan, Italy
    J Antimicrob Chemother 67:460-4. 2012
  3. ncbi Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient
    Dario Cattaneo
    Unit of Clinical Pharmacology, Luigi Sacco University Hospital, Universita di Milano, Milan, Italy
    Fundam Clin Pharmacol 26:204-6. 2012
  4. ncbi Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients
    Dario Cattaneo
    Unit of Clinical Pharmacology, Luigi Sacco University Hospital, Via GB Grassi 74, 20157 Milano, Italy
    J Clin Pharmacol 52:440-5. 2012
  5. ncbi Optimizing immunosuppressive drug dosing in pediatric renal transplantation. Part of a special series on Paediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni
    Dario Cattaneo
    Unit of Clinical Pharmacology, Luigi Sacco University Hospital, University of Milan, Via G B Grassi 74, Milan, Italy
    Pharmacol Res 65:163-7. 2012
  6. ncbi Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen
    Dario Cattaneo
    Unit of Clinical Pharmacology, Luigi Sacco University Hospital, Via GB Grassi, 74, 20157 Milan, Italy
    J Clin Pharmacol 49:773-81. 2009
  7. ncbi Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients
    Dario Cattaneo
    Unit of Clinical Pharmacology, Department of Clinical Sciences, Luigi Sacco University Hospital, Universita di Milano, Milan, Italy
    Ther Drug Monit 32:782-6. 2010
  8. ncbi Determination of linezolid in human plasma by high-performance liquid chromatography with ultraviolet detection
    Dario Cattaneo
    Unit of Clinical Pharmacology, Department of Preclinical Sciences, University Hospital Luigi Sacco, Universita di Milano, Milan, Italy
    Ther Drug Monit 32:520-4. 2010
  9. ncbi Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients
    Dario Cattaneo
    Unit of Clinical Pharmacology, Consiglio Nazionale delle Ricerche Institute of Neuroscience, Dept of Clinical Sciences L Sacco, University Hospital Luigi Sacco, Universita di Milano, Milan, Italy
    Pharmacol Res 65:198-203. 2012
  10. ncbi Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients
    Dario Cattaneo
    CNR Institute of Neuroscience and Unit of Clinical Pharmacology, Department of Clinical Sciences, Luigi Sacco University Hospital, Universita di Milano, Via GB Grassi 74, 20157 Milano, Italy Antiviral Therapy Unit, Infectious Diseases Unit Ospedali Riuniti di Bergamo, Largo Barozzi 1 24128 Bergamo, Italy E Medea Scientific Institute, Via Don Luigi Monza 23842 Bosisio Parini, Italy
    Fundam Clin Pharmacol 27:216-22. 2013

Collaborators

Detail Information

Publications14

  1. ncbi Comparison of the in vivo pharmacokinetics and in vitro dissolution of raltegravir in HIV patients receiving the drug by swallowing or by chewing
    Dario Cattaneo
    Department of Infectious Diseases, L Sacco University Hospital, Milan, Italy
    Antimicrob Agents Chemother 56:6132-6. 2012
    ..This is related to problems in tablet disintegration and to erratic drug absorption. The amelioration of the RAL pharmaceutical formulation could improve drug pharmacokinetics...
  2. ncbi Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects
    Dario Cattaneo
    Unit of Clinical Pharmacology, Luigi Sacco University Hospital, Universita di Milano, Milan, Italy
    J Antimicrob Chemother 67:460-4. 2012
    ..The present study was designed to evaluate in parallel the inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected patients during routine therapeutic drug monitoring (TDM)...
  3. ncbi Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient
    Dario Cattaneo
    Unit of Clinical Pharmacology, Luigi Sacco University Hospital, Universita di Milano, Milan, Italy
    Fundam Clin Pharmacol 26:204-6. 2012
    ..This case underlines the importance of traditional and pharmacogenetic-based TDM for the individualization of ATV therapy in HIV-1 patients...
  4. ncbi Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients
    Dario Cattaneo
    Unit of Clinical Pharmacology, Luigi Sacco University Hospital, Via GB Grassi 74, 20157 Milano, Italy
    J Clin Pharmacol 52:440-5. 2012
    ..These models could used to predict raltegravir exposure for clinic or research purposes...
  5. ncbi Optimizing immunosuppressive drug dosing in pediatric renal transplantation. Part of a special series on Paediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni
    Dario Cattaneo
    Unit of Clinical Pharmacology, Luigi Sacco University Hospital, University of Milan, Via G B Grassi 74, Milan, Italy
    Pharmacol Res 65:163-7. 2012
    ....
  6. ncbi Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen
    Dario Cattaneo
    Unit of Clinical Pharmacology, Luigi Sacco University Hospital, Via GB Grassi, 74, 20157 Milan, Italy
    J Clin Pharmacol 49:773-81. 2009
    ..These tools provide additional information to optimize SRL therapeutic drug monitoring in renal transplant recipients...
  7. ncbi Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients
    Dario Cattaneo
    Unit of Clinical Pharmacology, Department of Clinical Sciences, Luigi Sacco University Hospital, Universita di Milano, Milan, Italy
    Ther Drug Monit 32:782-6. 2010
    ..This pharmacokinetic drug interaction could be handled by routine measurements of ATV trough concentrations and by the assessment of plasma RAL concentrations 2 to 3 hours after the morning drug intake...
  8. ncbi Determination of linezolid in human plasma by high-performance liquid chromatography with ultraviolet detection
    Dario Cattaneo
    Unit of Clinical Pharmacology, Department of Preclinical Sciences, University Hospital Luigi Sacco, Universita di Milano, Milan, Italy
    Ther Drug Monit 32:520-4. 2010
    ..Mean drug recovery was 99.8% for linezolid and 90.0% for the internal standard (para-toluic acid). The method was found to be precise and accurate and suitable for therapeutic drug monitoring of linezolid in routine clinical practice...
  9. ncbi Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients
    Dario Cattaneo
    Unit of Clinical Pharmacology, Consiglio Nazionale delle Ricerche Institute of Neuroscience, Dept of Clinical Sciences L Sacco, University Hospital Luigi Sacco, Universita di Milano, Milan, Italy
    Pharmacol Res 65:198-203. 2012
    ....
  10. ncbi Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients
    Dario Cattaneo
    CNR Institute of Neuroscience and Unit of Clinical Pharmacology, Department of Clinical Sciences, Luigi Sacco University Hospital, Universita di Milano, Via GB Grassi 74, 20157 Milano, Italy Antiviral Therapy Unit, Infectious Diseases Unit Ospedali Riuniti di Bergamo, Largo Barozzi 1 24128 Bergamo, Italy E Medea Scientific Institute, Via Don Luigi Monza 23842 Bosisio Parini, Italy
    Fundam Clin Pharmacol 27:216-22. 2013
    ..These models could be used to predict atazanavir exposure for clinic or research purposes...
  11. ncbi Inflammation and neurological adverse drugs reactions: a case of long lasting impaired consciousness after oxatomide administration in a patient with gastroenteritis
    Stefania Antoniazzi
    Unit of Clinical Pharmacology, Department of Clinical Sciences, University Hospital Luigi Sacco, Universita di Milano, 20157 Milan, Italy
    Ital J Pediatr 38:11. 2012
    ..These findings highlight the importance of assessing common, not serious inflammatory states when oxatomide is prescribed in paediatric patients...
  12. ncbi Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans
    Clara Sciorati
    San Raffaele Scientific Institute, Stem Cell Research Institute, Milan, Italy
    Br J Pharmacol 160:1550-60. 2010
    ....
  13. ncbi Perceptions and patterns of use of generic drugs among Italian family pediatricians: first round results of a web survey
    Valentina Fabiano
    Department of Pediatrics, Universita degli Studi di Milano, Luigi Sacco Hospital, Via GB Grassi 74, Milan, Italy
    Health Policy 104:247-52. 2012
    ..More information about generic drugs and more research in the field of pediatric pharmacology are needed for increasing generic medicines prescription rate among Italian Family Pediatricians...
  14. ncbi Clinical pharmacokinetics of ibuprofen arginine
    Dario Cattaneo
    Department of Preclinical Sciences LITA Vialba, University of Milan, Via GB Grassi 74, Milan, Italy
    Curr Clin Pharmacol 5:239-45. 2010
    ..Taken together, the pharmacokinetic/dynamic characteristics of ibuprofen arginine can be considered particularly favorable for several clinical conditions, such as moderate/severe pain, in which a rapid pharmacologic effect is required...